Compare FMC Corp (FMC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Mesoblast Limited — how do they compare? FMC Corp trades at $10.48 (market cap $1.31B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Mesoblast Limited is the larger of the two by market cap, and FMC Corp pays a 3.06% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| FMC | MESO | |
|---|---|---|
Market Cap | $1.31B | $2.16B |
Sector | Basic Materials | Technology |
52-Week High | $40.69 | $20.96 |
52-Week Low | $10.01 | $12.88 |
Enterprise Value | $5.11B | $2.17B |
Dividend Yield | 3.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $10.59, up 0.38% today, with a bearish technical signal from moving averages. The stock shows mixed earnings beats but faces severe profitability challenges, with a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent news highlights revenue declines and cost management efforts, including a $400 million investment from Tessenderlo Group to reduce debt.
The outlook remains cautious due to persistent losses and competitive pressures in agricultural sciences. Upside exists if operational improvements and debt reduction stabilize finances, but high volatility and margin pressures pose significant risks to shareholder value.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
